Overexpression of Lysine-Specific Demethylase 1 Is Associated with Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma
Authors:
- 1 October 2015
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 25 (8) , 1453-1460
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin inductionNature Medicine, 2013
- Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent mannerBiochemical Journal, 2012
- Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breastBMC Clinical Pathology, 2012
- The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem CellsCancer Cell, 2012
- Personalized therapy in endometrial cancer: Challenges and opportunitiesCancer Biology & Therapy, 2012
- Multivariate survival analysis of the patients with recurrent endometrial cancerJournal of Gynecologic Oncology, 2011
- Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2Journal of the American Chemical Society, 2010
- Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biologyCarcinogenesis, 2009
- LSD1 and the chemistry of histone demethylationCurrent Opinion in Chemical Biology, 2007
- LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcriptionNature, 2005